✦ LIBER ✦

Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer

✍ Scribed by D Cunningham; R.D James

Book ID: 117657181
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 170 KB
Volume: 37
Category: Article
ISSN: 0959-8049
DOI: 10.1016/s0959-8049(01)00052-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Oral Fluoropyrimidines in the Treatment

Oral Fluoropyrimidines in the Treatment of Colorectal Cancer

✍ D. Bissett; F. Ahmed; H. McLeod; J. Cassidy 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 106 KB

Oral fluoropyrimidines in the treatment

Oral fluoropyrimidines in the treatment of colorectal cancer

✍ N.J Meropol 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 97 KB

Capecitabine, a new oral fluoropyrimidin

Capecitabine, a new oral fluoropyrimidine for the treatment of colorectal cancer

✍ Francesco Di Costanzo; Andrea Sdrobolini; Silvia Gasperoni 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 200 KB

Capecitabine (Xeloda) ® was developed as a tumour-selective fluoropyrimidine carbamate to achieve higher intratumoural 5-FU level and lower toxicity than 5-FU. Capecitabine passes unchanged through the gastrointestinal tract and is metabolised in the liver to 5%-deoxy-5-fluorocytidine (5%-DFCR). Her

Benefits and Drawbacks of the Use of Ora

Benefits and Drawbacks of the Use of Oral Fluoropyrimidines as Single-Agent Therapy in Advanced Colorectal Cancer

✍ Jim Cassidy 📂 Article 📅 2005 🏛 CIG Media Group, LP. 🌐 English ⚖ 871 KB

Integrating Radiation Into the Managemen

Integrating Radiation Into the Management of Vulvar Cancer

✍ Elizabeth A. Barnes; Gillian Thomas 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 623 KB

Factoring drug-free intervals into the m

Factoring drug-free intervals into the management of patients with advanced colorectal cancer

✍ Frédérique Maindrault-Goebel; Pascal Artru; Gérard Lledo; Benoist Chibaudel; Nat 📂 Article 📅 2007 🏛 Current Science Inc. 🌐 English ⚖ 283 KB